Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The median length of BP treatment in patients with and without fractures was 35 (16 to 49) months and 28 (11 to 44) months, respectively; no statistically significant difference was observed between the two groups (P = 0.282; Mann: Whitney U test).Patient characteristics at baselineParameterTotal(n = 98)Fractured(n = 20)Non-fractured(n = 78)Age (years old)69 (65 to 74)71 (67 to 75)69 (65 to 74)BMI (kg/m2)20.4 (18.7 to 22.9)20.1 (17.8 to 21.2)20.5 (19.0 to 23.4)Disease duration (months)80 (8 to 209)180 (56 to 270)63 (6 to 162)History of vertebral fracture, n (%)27 (27.6)14 (70.0)13 (16.7)SDAI(3.83 to 12.00)7.24 (4.70 to 11.87)6.73 (3.72 to 12.00)HAQ-DI0.50 (0.13 to 1.13)1.00 (0.50 to 1.63)0.44 (0.13 to 1.00)Rheumatoid factor positive, n (%)72 (73.5)16 (80.0)56 (71.8)Rheumatoid factor (IU/mL)45 (14 to 89)41 (23 to 80)45 (14 to 89)ACPA positive, n (%)75 (76.5)16 (80.0)59 (75.6)ACPA (U/mL)25 (5 to 250)33 (8 to 366)35 (3 to 234)CRP (mg/dL)0.18 (0.04 to 0.67)0.09 (0.01 to 0.83)0.19 (0.05 to 0.58)Concomitant oral glucocorticoid, n (%)49 (50.0)13 (65.0)36 (46.1)Dose of oral glucocorticoid (mg/day)0.2 (0 to 3.8)2.5 (0 to 3.0)0 (0 to 5.0)Dose of oral glucocorticoida (mg/day)4.0 (2.5 to 5.0)3.0 (2.5 to 3.5)5.0 (2.5 to 7.5)Concomitant methotrexate, n (%)78 (79.6)16 (80.0)62 (79.5)Dose of methotrexate (mg/week)6.0 (2.0 to 8.0)4.0 (2.0 to 8.0)8.0 (4.0 to 8.0)Dose of methotrexatea (mg/week)8.0 (6.0 to 10.0)6.0 (4.0 to 8.5)8.0 (6.0 to 10.0)Concomitant bDMARDs, n (%)33 (33.7)9 (45.0)24 (30.8)Lumbar BMD (g/cm2)0.73 (0.66 to 0.82)0.73 (0.63 to 0.83)0.73 (0.66 to 0.81)Total hip BMD (g/cm2)0.62 (0.56 to 0.68)0.56 (0.50 to 0.65)0.62 (0.58 to 0.68)Vitamin D supplementation, n (%)27 (27.6)3 (15.0)24 (30.8)Type of oral BP, n (%)Alendronate14 (14.3)5 (25.0)9 (11.5)Risedronate24 (24.5)6 (30.0)18 (23.1)Minodronate60 (61.2)9 (45.0)51 (65.4)Length of BP treatment (months)28 (11 to 45)35 (16 to 49)28 (11 to 44)Continuous variables were presented as the median with interquartile range, and categorical variables were presented as numbers with percentagesBMI, Body mass index; SDAI, Simplified Disease Activity Index; HAQ-DI, Health Assessment Questionnaire Disability Index; ACPA, anticyclic citrullinated protein antibodies; CRP, C-reactive protein; bDMARDs, biological disease-modifying antirheumatic drugs; BMD, bone mineral density; BP, bisphosphonatesaMedian (interquartile range) among patients receiving drugs
Source: Patient characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study
Source: Article title.
All eligible patients fulfilled the inclusion criteria as follows: postmenopausal women aged ≥ 50 years with RA who met the 2010 American College of Rheumatology/European League Against Rheumatism criteria [], patients who met our indication of pharmacologic treatment for osteoporosis in patients with RA as described later in this paper, and patients who were newly prescribed oral BP.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study
Observational study · BMC Rheumatology · 2022
Original publication title
Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Although many studies have reported the predictors of fractures in patients with rheumatoid arthritis (RA) who are not receiving anti-osteoporotic treatments or who are receiving unspecified treatments, studies focusing on the predictors of fracture in patients with RA who are currently being treated with oral bisphosphonates (BP) are quite scarce. This study aims to investigate the incidence and predictors of fragility fracture in postmenopausal patients with RA receiving oral BP.
Source: BackgroundAbstract: What methods does the paper describe?
This retrospective longitudinal observational study comprised 98 postmenopausal RA patients receiving oral BP for a minimum of 6 months between April 2015 and December 2020. The cumulative incidence of fragility fractures including vertebral and nonvertebral fractures was investigated using the Kaplan: Meier method. Cox proportional hazards analysis was used to analyze baseline predictors of future fragility fractures. To determine a cutoff value of continuous predictors, the receiver-operating characteristic curve was applied.
Source: MethodsAbstract: Results
Twenty patients developed fractures during the study period, with a cumulative incidence of 6.1% at 12 months, 10.5% at a median follow-up of 28 months, and 14.4% at 36 months. Multivariable Cox hazards analysis showed a history of prior vertebral fracture (hazard ratio [HR] 6.26, 95% confidence interval [CI] 1.99 to 19.68, P = 0.001) and dose of methotrexate (HR 0.87, 95% CI 0.76 to 0.99, P = 0.041) to be independent predictors. The cutoff value for methotrexate dose was 4 mg/week.
Source: ResultsAbstract: Conclusions
We found a cumulative incidence of any fractures of 10.5% at 28 months in patients with RA currently being treated with oral BP. A history of prior vertebral fractures and methotrexate dose were positive and negative predictors for fractures, respectively. Practitioners should consider selecting another anti-osteoporotic drug in patients with RA who remain at risk despite receiving oral BP.
Source: ConclusionsAuthors’ abstract
Background
Although many studies have reported the predictors of fractures in patients with rheumatoid arthritis (RA) who are not receiving anti-osteoporotic treatments or who are receiving unspecified treatments, studies focusing on the predictors of fracture in patients with RA who are currently being treated with oral bisphosphonates (BP) are quite scarce. This study aims to investigate the incidence and predictors of fragility fracture in postmenopausal patients with RA receiving oral BP.
Methods
This retrospective longitudinal observational study comprised 98 postmenopausal RA patients receiving oral BP for a minimum of 6 months between April 2015 and December 2020. The cumulative incidence of fragility fractures including vertebral and nonvertebral fractures was investigated using the Kaplan: Meier method. Cox proportional hazards analysis was used to analyze baseline predictors of future fragility fractures. To determine a cutoff value of continuous predictors, the receiver-operating characteristic curve was applied.
Results
Twenty patients developed fractures during the study period, with a cumulative incidence of 6.1% at 12 months, 10.5% at a median follow-up of 28 months, and 14.4% at 36 months. Multivariable Cox hazards analysis showed a history of prior vertebral fracture (hazard ratio [HR] 6.26, 95% confidence interval [CI] 1.99 to 19.68, P = 0.001) and dose of methotrexate (HR 0.87, 95% CI 0.76 to 0.99, P = 0.041) to be independent predictors. The cutoff value for methotrexate dose was 4 mg/week.
Conclusions
We found a cumulative incidence of any fractures of 10.5% at 28 months in patients with RA currently being treated with oral BP. A history of prior vertebral fractures and methotrexate dose were positive and negative predictors for fractures, respectively. Practitioners should consider selecting another anti-osteoporotic drug in patients with RA who remain at risk despite receiving oral BP.
Publication and source details
Original title: Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study
Yuji Kishimoto; Yoshihiro Kato; Manami Uemura; Koji Kuranobu
BMC Rheumatology · 2022
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T10:08:54.919181+00:00
DOI: 10.1186/s41927-021-00243-x · PMC8883631